Ocular surface disease may be present at baseline in patients with AD treated with dupilumab. News & Perspective ... adding that 71% of the group also reported allergic conjunctivitis at ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

In a post-hoc analysis, dupilumab improved symptoms of atopic dermatitis (AD) in young children ages 6 months to 5 years. Youngsters with associated comorbidities such as asthma, allergic rhinitis ...

The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Dupilumab has been approved by the FDA for the treatment bullous pemphigoid in adults, the manufacturer Regeneron announced.. Dupilumab (Dupixent), a human monoclonal antibody that inhibits ...

Regarding DSQ scores, researchers saw sustained improvements for patients who continued dupilumab from Group A through Group C (mean change from baseline, –23.44 points; 95% CI, –29.58 to ...

Lebrikizumab, tralokinumab and dupilumab to compete in atopic dermatitis space. ... conjunctivitis and risk of skin infections. The incidence of trial discontinuation due to adverse events was low.

Dupilumab (Dupixent), a medicine that you get as a shot, is the first new treatment for CSU in the U.S. in over a decade. It’s already used to treat different inflammation conditions in the U.S ...

Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis If approved, Dupixent would be the first and only ...